Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erica Schweinsberg

Physician Assistant Pittsburgh, PA Physician Assistant

NPI 1760968010 CMS profile 10686489

1000 Cliffmine Rd Ste 110, Pittsburgh, PA 15275

Open in the dashboard

General payments

$6,900

438 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erica Schweinsberg of Pittsburgh, PA is reported in the CMS Open Payments database as having received $6,900 across 438 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,121 68
2024 General $1,440 93
2023 General $1,504 93
2022 General $1,309 76
2021 General $1,526 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erica Schweinsberg
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Erica Schweinsberg were reported at $1,121. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Erica Schweinsberg Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,526 $132 $37–$438 $132
2022 $1,309 $155 $48–$522 $149
2023 $1,504 $167 $52–$557 $160
2024 $1,440 $178 $55–$600 $164
2025 $1,121 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,552 147 payments
  2. Lilly USA, LLC $931 65 payments
  3. Novo Nordisk Inc $585 40 payments
  4. GlaxoSmithKline, LLC. $571 37 payments
  5. Amgen Inc. $536 54 payments
  6. AstraZeneca Pharmaceuticals LP $487 21 payments
  7. Biohaven Pharmaceuticals, Inc. $260 14 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $118 7 payments
  9. Sanofi-Aventis U.S. LLC $98 6 payments
  10. Exact Sciences Corporation $94 6 payments
  11. Other $667 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,900 438 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,317 80 payments
  2. QULIPTA $949 49 payments
  3. TRELEGY ELLIPTA $551 35 payments
  4. VRAYLAR $531 33 payments
  5. Ozempic $383 28 payments
  6. Otezla $383 39 payments
  7. FARXIGA $373 14 payments
  8. MOUNJARO $362 27 payments
  9. JARDIANCE $334 24 payments
  10. RYBELSUS $328 25 payments
  11. Other $3,042 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

3,131

Median for Physician Assistant: 241

Drug cost

$221,417

Median for Physician Assistant: $4,110

Branded share of claims

20.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 45 $49,077
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 46 $43,261
Mounjaro Tirzepatide Brand 33 $34,066
Eliquis Apixaban Brand 25 $21,788
Farxiga Dapagliflozin Propanediol Brand 12 $14,517
Repatha Sureclick Evolocumab Brand 15 $11,431
Vascepa Icosapent Ethyl Brand 25 $8,808
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 11 $3,386
Duloxetine Hcl Generic 64 $2,688
Atorvastatin Calcium Generic 243 $2,437

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $217
$217 — —
QULIPTA
  • AbbVie, Inc. $196
$196 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $146
$146 46 —
MOUNJARO
  • Lilly USA, LLC $106
$106 33 —
Wegovy
  • Novo Nordisk Inc $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

438 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record